These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 24070806)

  • 1. Resistance to HCV nucleoside analogue inhibitors of hepatitis C virus RNA-dependent RNA polymerase.
    Najera I
    Curr Opin Virol; 2013 Oct; 3(5):508-13. PubMed ID: 24070806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-hepatitis C virus RdRp activity and replication of novel anilinobenzothiazole derivatives.
    Peng HK; Chen WC; Lin YT; Tseng CK; Yang SY; Tzeng CC; Lee JC; Yang SC
    Antiviral Res; 2013 Oct; 100(1):269-75. PubMed ID: 23994188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection.
    Sheldon J; Barreiro P; Soriano V
    Expert Opin Investig Drugs; 2007 Aug; 16(8):1171-81. PubMed ID: 17685867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the molecular targets for new therapeutical agents in hepatitis c infection.
    Vagu C; Sultana C; Ruţă S
    Roum Arch Microbiol Immunol; 2013; 72(1):5-24. PubMed ID: 23947011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus-specific directly acting antiviral drugs.
    Delang L; Neyts J; Vliegen I; Abrignani S; Neddermann P; De Francesco R
    Curr Top Microbiol Immunol; 2013; 369():289-320. PubMed ID: 23463206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-free strategies without a nucleoside/nucleotide analogue.
    Welzel TM; Zeuzem S
    Semin Liver Dis; 2014 Feb; 34(1):47-57. PubMed ID: 24782258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New possibilities on the horizon for the treatment of hepatitis C virus infection: direct-acting antiviral therapy].
    Pár A
    Orv Hetil; 2010 Dec; 151(50):2045-56. PubMed ID: 21126947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA dependent RNA polymerase of HCV: a potential target for the development of antiviral drugs.
    Waheed Y; Bhatti A; Ashraf M
    Infect Genet Evol; 2013 Mar; 14():247-57. PubMed ID: 23291407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-nucleoside inhibitors of the HCV polymerase.
    Sarisky RT
    J Antimicrob Chemother; 2004 Jul; 54(1):14-6. PubMed ID: 15190019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current race in the development of DAAs (direct-acting antivirals) against HCV.
    De Clercq E
    Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
    Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
    Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibitors of hepatitis C virus replication.
    Neyts J
    Antiviral Res; 2006 Sep; 71(2-3):363-71. PubMed ID: 16843538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New non-nucleoside inhibitors of hepatitis C virus RNA-dependent RNA polymerase.
    Ivanov AV; Kozlov MV; Kuzyakin AO; Kostyuk DA; Tunitskaya VL; Kochetkov SN
    Biochemistry (Mosc); 2004 Jul; 69(7):782-8. PubMed ID: 15310279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of hepatitis C: current status and perspectives].
    Pol S; Corouge M
    Rev Prat; 2014 May; 64(5):605-12. PubMed ID: 24923038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.
    Wyles DL; Gutierrez JA
    J Viral Hepat; 2014 Apr; 21(4):229-40. PubMed ID: 24597691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fluorescence-based high-throughput screen to identify small compound inhibitors of the genotype 3a hepatitis C virus RNA polymerase.
    Eltahla AA; Lackovic K; Marquis C; Eden JS; White PA
    J Biomol Screen; 2013 Oct; 18(9):1027-34. PubMed ID: 23708123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C treatment: an incipient therapeutic revolution.
    deLemos AS; Chung RT
    Trends Mol Med; 2014 Jun; 20(6):315-21. PubMed ID: 24636306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SCREENING OF PROTEASE INHIBITORS RESISTANCE MUTATIONS IN HEPATITIS C VIRUS ISOLATES INFECTING ROMANIAN PATIENTS UNEXPOSED TO TRIPLE THERAPY.
    Dinu S; Calistru PI; Ceauşu E; Târdeil G; Oprişan G
    Roum Arch Microbiol Immunol; 2015; 74(1-2):7-17. PubMed ID: 26727849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel resistance mutation for benzimidazole inhibitors of the HCV RNA-dependent RNA polymerase.
    Delang L; Froeyen M; Herdewijn P; Neyts J
    Antiviral Res; 2012 Jan; 93(1):30-8. PubMed ID: 22033247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.